MS and Demyelinating Disorders

Although challenging, shared decision-making is a rewarding part of the practice of medicine. Involving patients in therapeutic decisions can improve patient autonomy and satisfaction—but it is not easy to implement.

Christy Sheehy, PhD, chief executive officer and cofounder of C. Light Technologies, talked about the FDA clearance of Retitrack—retinal eye-movement monitor—and how the device holds promise for facilitating more accurate ocular motor assessments at bedside.

The professor of neurology at Washington University School of Medicine discussed the growing sense of hope among patients with progressive multiple sclerosis as providers gain an understanding in treating this form of the disease. [WATCH TIME: 3 minutes]

Here's the latest multidisciplinary MS research published online first in the International Journal of MS Care.

Here's some of what is coming soon to NeurologyLive® this week.

The director of pharmacy at Emory Healthcare and Winship Cancer Institute talked about the role of pharmacists in multiple sclerosis patient care and collaborating with providers as biosimilars become available. [WATCH TIME: 5 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is neuromuscular disorders.

Time to the first clinical event was significantly extended in the teriflunomide arm compared with placebo, in both the unadjusted and adjusted analysis.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 25, 2023.

The neuromuscular and movement disorders speech-language pathologist at Orlando Health discussed strategies in managing the phases of multiple sclerosis for patients and the need for collaborative referral practices. [WATCH TIME: 5 minutes]

The injection therapy, branded as Tyruko, is indicated for the treatment of adults with MS, as well as those with severely active Crohn disease with inadequate response or tolerability to conventional therapy.

Autologous hematopoietic stem cell transplant was associated with a higher rate of recovery from disability than fingolimod and natalizumab, especially during the initial year posttreatment.

The assistant professor at Queen’s University discussed results from a pilot trial that evaluated the impact of a dyadic physical activity intervention among both caregivers and patients with multiple sclerosis. [WATCH TIME: 3 minutes]

According to a recent study, malnutrition is related closely to quality of life among patients with NMOSD, caused by a variety of physiological and psychological factors.

Experts share insights on the latest innovations in multiple sclerosis research, in highlights from a recent State of the Science SummitTM, presented by Neurology Live®.

The executive vice president of the National MS Society provided perspective on the challenges with remyelinating strategies for patients with MS, and the progress that’s been made thus far. [WATCH TIME: 4 minutes]

The assistant professor at Hunter College talked about the importance of prioritizing accurate localization, appropriate diagnostic tests, and patient communication for effective neurological diagnosis, prognosis, and treatment. [WATCH TIME: 3 minutes]

Among a cohort of more than 70 individuals with MS, only 1 relapse occurred while on eculizumab, with significant reductions in immunosuppressive use observed.

The director of the Buffalo Neuroimaging Analysis Center talked about a study that explored cognitive decline in patients with early multiple sclerosis, underlining the significance of addressing cognitive impairment in the early stages of the disease. [WATCH TIME: 3 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is headache and migraine.

IMU-838, or vidofludimus calcium, has shown promising results in studies of patients with relapsing-remitting multiple sclerosis.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 18, 2023.

The executive vice president of the National MS Society discussed the challenges with treating progressive forms of MS, and the accumulating neurodegeneration seen over time. [WATCH TIME: 4 minutes]

Here's some of what is coming soon to NeurologyLive® this week.